Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46148

1.

In Vivo Study of the Effects of ERβ on Apoptosis and Proliferation of Hormone-Independent Prostate Cancer Cell Lines PC-3M.

Zhou C, Yu C, Guo L, Wang X, Li H, Cao Q, Li F.

Biomed Res Int. 2018 Jun 19;2018:1439712. doi: 10.1155/2018/1439712. eCollection 2018.

2.

Scandinavian Prostate Cancer Patients' Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment.

Hald GM, Pind MD, Borre M, Lange T.

Sex Med. 2018 Jul 12. pii: S2050-1161(18)30056-4. doi: 10.1016/j.esxm.2018.06.002. [Epub ahead of print]

3.

Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients.

Schaake W, van der Schaaf A, van Dijk LV, van den Bergh ACM, Langendijk JA.

PLoS One. 2018 Jul 17;13(7):e0197757. doi: 10.1371/journal.pone.0197757. eCollection 2018.

4.

Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes.

van Dessel LF, Reuvers SHM, Bangma CH, Aluwini S.

Clin Transl Radiat Oncol. 2018 May 29;11:26-32. doi: 10.1016/j.ctro.2018.05.001. eCollection 2018 Jun.

5.

Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer.

Kotabe K, Nakayama H, Takashi A, Takahashi A, Tajima T, Kume H.

Oncol Lett. 2018 Aug;16(2):2741-2749. doi: 10.3892/ol.2018.8888. Epub 2018 Jun 4.

6.

Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3β/Snail signaling pathway.

Fang F, Chen S, Ma J, Cui J, Li Q, Meng G, Wang L.

Oncol Lett. 2018 Aug;16(2):2579-2584. doi: 10.3892/ol.2018.8885. Epub 2018 Jun 4.

7.

Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis.

Luo G, He Y, Yu X.

Front Endocrinol (Lausanne). 2018 Jun 22;9:339. doi: 10.3389/fendo.2018.00339. eCollection 2018. Review.

8.

The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study.

Song W, Yu JW, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Kang ES, Jeon HG.

Onco Targets Ther. 2018 Jul 6;11:3883-3889. doi: 10.2147/OTT.S169094. eCollection 2018.

9.

Loss of miR-516a-3p mediates upregulation of ABCC5 in prostate cancer and drives its progression.

Zhang H, Lian Z, Sun G, Liu R, Xu Y.

Onco Targets Ther. 2018 Jul 6;11:3853-3867. doi: 10.2147/OTT.S167463. eCollection 2018.

10.

A Supervised Learning Tool for Prostate Cancer Foci Detection and Aggressiveness Identification using Multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging.

Kirlik G, Gullapalli R, D'Souza W, Md Daud Iqbal G, Naslund M, Wong J, Papadimitrou J, Roys S, Mistry N, Zhang H.

Cancer Inform. 2018 Jul 10;17:1176935118786260. doi: 10.1177/1176935118786260. eCollection 2018.

11.

Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis.

Tae BS, Cho S, Kim HC, Kim CH, Kang SH, Lee JG, Kim JJ, Park HS, Cheon J, Oh MM, Kang SG.

Sci Rep. 2018 Jul 16;8(1):10748. doi: 10.1038/s41598-018-28566-9.

12.

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.

Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X.

J Exp Clin Cancer Res. 2018 Jul 16;37(1):153. doi: 10.1186/s13046-018-0810-7.

13.

Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study.

Shin DW, Lee SH, Kim TH, Yun SJ, Nam JK, Jeon SH, Park SC, Jung SI, Park JH, Park J.

Cancer Res Treat. 2018 Jul 16. doi: 10.4143/crt.2018.221. [Epub ahead of print]

14.

Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?

Poluri RTK, Audet-Walsh É.

Front Oncol. 2018 Jun 29;8:246. doi: 10.3389/fonc.2018.00246. eCollection 2018.

15.

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.

Hakozaki Y, Murata T, Yokoyama M, Matsushima H, Ogawa M, Masuda T, Hirai Y, Kume H.

Urol Case Rep. 2018 Jul 7;20:67-69. doi: 10.1016/j.eucr.2018.07.008. eCollection 2018 Sep.

16.

Stereotactic Body Radiation Therapy for Prostate Cancer: An Institutional Experience Using MRI-guided Treatment Planning.

Waheed NL, Yoder AK, Van Wyhe RD, Carpenter SL.

Cureus. 2018 May 8;10(5):e2590. doi: 10.7759/cureus.2590.

17.

The Effect of Steep Trendelenburg Positioning on Retinal Structure and Function during Robotic-Assisted Laparoscopic Procedures.

Hirooka K, Ukegawa K, Nitta E, Ueda N, Hayashida Y, Hirama H, Taoka R, Sakura Y, Yamasaki M, Tsunemori H, Sugimoto M, Kakehi Y.

J Ophthalmol. 2018 Jun 13;2018:1027397. doi: 10.1155/2018/1027397. eCollection 2018.

18.

Effects of connective tissue growth factor on prostate cancer bone metastasis and osteoblast differentiation.

Zhang S, Li B, Tang W, Ni L, Ma H, Lu M, Meng Q.

Oncol Lett. 2018 Aug;16(2):2305-2311. doi: 10.3892/ol.2018.8960. Epub 2018 Jun 13.

19.

Suppressed epithelial-mesenchymal transition and cancer stem cell properties mediate the anti-cancer effects of ethyl pyruvate via regulation of the AKT/nuclear factor-κB pathway in prostate cancer cells.

Huang B, Lv DJ, Wang C, Shu FP, Gong ZC, Xie T, Yu YZ, Song XL, Xie JJ, Li S, Liu YM, Qi H, Zhao SC.

Oncol Lett. 2018 Aug;16(2):2271-2278. doi: 10.3892/ol.2018.8958. Epub 2018 Jun 12.

20.

Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin.

Huang F, Wang P, Wang X.

Oncol Lett. 2018 Aug;16(2):1975-1980. doi: 10.3892/ol.2018.8833. Epub 2018 May 30.

Supplemental Content

Loading ...
Support Center